New injection fights head and neck cancer from the inside
NCT ID NCT06736379
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment called VLPONC-01, which is injected directly into head and neck tumors. It delivers a substance (IL-12) that may help the immune system attack the cancer. Some participants will also receive the immunotherapy drug pembrolizumab. The main goal is to check safety and see if the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VLPONC-01 (a virus-based therapy that delivers IL-12 into tumors) and pembrolizumab (an immunotherapy drug)
What this could lead to
If successful, this could point toward a new treatment option for head and neck cancer that boosts the immune system to fight tumors.
What could go wrong
This is a very early (Phase 1) trial with only 41 participants, so safety and effectiveness are not yet proven. There is a risk of side effects from the injections or the combination therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGStanford, California, 34305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact